Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhu-pGSN to Mitigate Proinflammatory Responses to Decompression
NCT06216366Phase 2Completed
- Sponsor
- BioAegis Therapeutics
- Start
- Aug 2025
- Primary completion
- Sep 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of Recombinant human plasma gelsolin in decompression sickness (DCS), sponsored by BioAegis Therapeutics. Started Aug 2025; status: completed.
02
Drugs
Recombinant human plasma gelsolin
03
Conditions
decompression sickness (DCS)
Beyond the preview
Go deeper on NCT06216366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06216366.